Health Information and Tools >  Reducing Cancer Risk When You Are BRCA-Positive

Main Content

Reducing Cancer Risk When You Are BRCA-Positive

Overview

BRCA1 and BRCA2 are genes that help repair damaged DNA and protect against cancer. But having a pathogenic variant in one of these genes stops the gene from working well. This means you will have a higher-than-average risk to develop breast, ovarian, and some other cancers. BRCA (say "BRAH-kuh") stands for "BReast CAncer."

BRCA pathogenic variants aren't common. Your doctor may talk to you about testing based on your family medical history or your personal medical history. Your doctor may ask you questions, such as if you have family members who had breast or ovarian cancer, if you were diagnosed with breast cancer before age 50, or if you have an Ashkenazi Jewish heritage.

If you are concerned that you may have a BRCA pathogenic variant, talk with your doctor. The BRCA1 and BRCA2 genes are not the only genes that help protect against cancer, and pathogenic variants in other genes can also increase your risk of developing cancer.

In the table below, the figures are only rough estimates from research studies of females. These numbers may not apply to you, but they can give you an idea of how high your risk may be. footnote 1

How does having a BRCA pathogenic variant affect your risk?

Breast cancer risk

Ovarian cancer risk

Females without a BRCA pathogenic variant

About 13 out of 100 will get breast cancer sometime during their lives.

About 1 out of 100 will get ovarian cancer sometime during their lives.

Those with BRCA1 pathogenic variant

About 72 out of 100 will get breast cancer by age 80.

About 44 out of 100 will get ovarian cancer by age 80.

Those with BRCA2 pathogenic variant

About 69 out of 100 will get breast cancer by age 80.

About 17 out of 100 will get ovarian cancer by age 80.

Genetic testing can show if you have a pathogenic variant that increases your risk for breast cancer and ovarian cancer. Before you have genetic testing, you may want to see a genetic counsellor. Genetic counselling will help you decide about genetic testing.

In Alberta, genetic testing is covered by the Alberta Health Care Insurance Plan if your medical history or if your medical and family history show possible signs of hereditary cancer. Genetic counsellors and healthcare providers look at many factors to determine who is eligible for genetic testing.

Ways to reduce cancer risk

Experts know that people who have a BRCA pathogenic variant are more likely to get breast cancer and ovarian cancer. If you have a BRCA pathogenic variant, you can take steps to reduce your risk of these cancers.

To help those with BRCA pathogenic variants, experts study women with BRCA pathogenic variants to predict how much breast and ovarian cancer risk could be reduced by certain methods. These methods include:

  • Having the breasts removed (mastectomy).
  • Having the fallopian tubes and ovaries removed (salpingectomy and oophorectomy).
  • Having a mammogram every year starting at age 30 and breast MRI every year starting at age 25. These screening tests don't prevent breast cancer. But they can find cancer early, when a cure is most likely.

The results of a study from 2010 are shown in the tables below.

The study also looked at having the surgeries at different ages. For example, you can see what difference it might make if you keep your breasts and ovaries until you're past your childbearing years. These results are one piece of information you can use as you explore how to lower your cancer risk. Your doctor or genetic counsellor can discuss the most up-to-date information about ways to lower your cancer risk.

Surgery and screening tests are not your only options. You can also talk to your doctor about medicines, such as tamoxifen. Or you may choose to have no treatment or extra screening.

Women with BRCA1 pathogenic variants

According to the study, here's how the different prevention methods affect the lifespans of those with BRCA1 pathogenic variants. footnote 2

Comparing prevention methods for women with BRCA1 pathogenic variants

Prevention method

Those who live to age 70 after this method

No treatment or extra screening.

53 out of 100

Annual breast screening.

59 out of 100

Ovaries and fallopian tubes removed at age 50.

61 out of 100

Breasts removed at age 40.

64 out of 100

Breasts removed at age 25.

66 out of 100

Ovaries and fallopian tubes removed at age 40.

68 out of 100

Annual screening + ovaries and fallopian tubes removed at age 40.

76 out of 100

Annual screening + breasts, ovaries and fallopian tubes removed at age 40.

77 out of 100

Breasts removed at age 25 + ovaries and fallopian tubes removed at age 40.

79 out of 100

Women with BRCA2 pathogenic variants

According to the study, here's how the different prevention methods affect the lifespans of those with BRCA2 pathogenic variants. footnote 2

Comparing prevention methods for women with BRCA2 pathogenic variants

Prevention method

Those who live to age 70 after this method

No treatment or extra screening.

71 out of 100

Annual screening.

75 out of 100

Ovaries and fallopian tubes removed at age 50.

75 out of 100

Ovaries and fallopian tubes removed at age 40.

77 out of 100

Annual screening + breasts removed at age 40.

78 out of 100

Breasts removed at age 25.

79 out of 100

Annual screening + ovaries and fallopian tubes removed at age 40.

81 out of 100

Annual screening + breasts, ovaries, and fallopian tubes removed at age 40.

82 out of 100

Breasts removed at age 25 + ovaries and fallopian tubes removed at age 40.

83 out of 100

Deciding about your options

Take some time to think about your options. A genetic counsellor can help you understand how the prevention options affect your cancer risk. You may want to discuss them with your family and close friends. Then you can reach a decision that is right for you.

References

Citations

  1. Kuchenbaecker KB, et al. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA, 317(23): 2402–2416. DOI: 10.1001/jama.2017.7112. Accessed August 5, 2020.
  2. Kurian AW, et al. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of Clinical Oncology, 28(2): 222–231. Also available online: http://jco.ascopubs.org/content/28/2/222.full.

Credits

Adaptation Date: 09/28/2026

Adapted By: Alberta Health Services

Adaptation Reviewed By: Alberta Health Services

Adaptation Date: 09/28/2026

Adapted By: Alberta Health Services

Adaptation Reviewed By: Alberta Health Services

Adapted with permission from copyrighted materials from Ignite Healthwise, LLC (Healthwise). This information does not replace the advice of a doctor. Healthwise disclaims any warranty and is not responsible or liable for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

​